Skip to main content
Premium Trial:

Request an Annual Quote

Oncotest-Teva to Distribute Guardant Health Liquid Biopsy Test in Israel

NEW YORK (GenomeWeb) – Guardant Health said yesterday that it has signed an exclusive distribution and marketing partnership with Teva Pharmaceuticals subsidiary Oncotest-Teva to make Guardant Health's Guardant360 available to patients with advanced cancer in Israel.

One of the first commercially available laboratory-developed liquid biopsy tests in the US, Guardant360 detects and analyzes DNA fragments shed from solid tumors into the blood of patients with advanced cancers, including all four major classes of somatic genomic alterations.

According to Guardant, Oncotest-Teva will market the test and handle local sample logistics and patient reimbursement in Israel. Guardant Health, meanwhile, will still perform all testing in its CLIA-certified, CAP-accredited facilities in Redwood City, California.

Oncotest-Teva also furnishes the Israeli market with a number of other genomic cancer tests including hereditary cancer gene testing, targeted and comprehensive tumor tissue sequencing, and gene expression-based assays.